Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Bernier-Chastagner V, Padovani L, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB.
Dufour C, et al. Among authors: berger c.
Neuro Oncol. 2021 Jul 1;23(7):1163-1172. doi: 10.1093/neuonc/noaa301.
Neuro Oncol. 2021.
PMID: 33377141
Free PMC article.
Clinical Trial.